Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 5/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | RAF1 | P04049 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5592888 | 0.93 | EPHB4 (0.54) | EPHB4TRPV1MAPTKDRERBB4 | |
| SCHEMBL5592620 | 0.92 | EPHB4 (0.47) | EPHB4TRPV1MAPTKDRERBB4 | |
| SCHEMBL5671277 | 0.86 | EPHB4 (0.49) | EPHB4BRAFTRPV1RAF1MAPT | |
| SCHEMBL5593089 | 0.86 | EPHB4 (0.54) | EPHB4BRAFTRPV1RAF1MAPT | |
| SCHEMBL5592903 | 0.86 | MAPT (0.47) | EPHB4RAF1MAPTERBB4ALDH1A1 | |
| SCHEMBL5592628 | 0.85 | ERBB4 (0.43) | EPHB4MAPTKDRERBB4TEK | |
| SCHEMBL5592578 | 0.84 | TRPV1 (0.57) | EPHB4BRAFTRPV1KDRFLT1 | |
| SCHEMBL12028947 | 0.83 | THRA (0.44) | EPHB4MAPTERBB4ALDH1A1MEN1 | |
| SCHEMBL5592636 | 0.83 | TRPV1 (0.42) | EPHB4BRAFTRPV1KDRFLT1 | |
| SCHEMBL5592480 | 0.83 | EPHB4 (0.47) | EPHB4BRAFTRPV1RAF1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | claimed |
| EP-1858879-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-07 | — | — | US | claimed |
| WO-2006076593-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-1858879-B1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2397478-A1 | 1,3-diaryl substituted ureas as modulators of kinase activity. | CGI Pharmaceuticals, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397478-A1 | 1,3-diaryl substituted ureas as modulators of kinase activity. | CGI Pharmaceuticals, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-1858879-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006076593-A1 | 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199846-A1 | Certain substituted ureas as modulators of kinase activity | UCK2, CHUK, AXL | EPHB4 3357/4885BRAF 55/4885TRPV1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.